Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026

Acumen plans a virtual Investor Day with live call, webcast access and a year-long replay available to investors.

Rhea-AI Summary

Acumen Pharmaceuticals (ABOS) will host a virtual Investor Day on Wednesday, September 16, 2026, at 10:00 a.m. ET.

Participants can join the live conference call by registering through the specified link, after which dial-in numbers and a PIN will be provided. A simultaneous webcast will be accessible via a separate link, and an archived replay will be hosted for at least one year in the Investors section of Acumen’s website.

Acumen is a clinical-stage biopharmaceutical company focused on Alzheimer’s disease, advancing its lead antibody sabirnetug (ACU193) in the Phase 2 ALTITUDE-AD trial after positive Phase 1 INTERCEPT-AD results, and pursuing additional programs with Halozyme and JCR Pharmaceuticals.

Key Terms

monoclonal antibody, blood-brain barrier

2 terms

monoclonal antibody medical

"a humanized monoclonal antibody that selectively targets toxic soluble AβOs"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

blood-brain barrier medical

"a transferrin-receptor-targeting blood-brain barrier-penetrating technology"

A protective barrier of tightly packed cells and supporting tissue that controls what substances in the blood can enter the brain, acting like a security checkpoint that keeps out most pathogens and many drugs while allowing essential nutrients through. For investors, the barrier matters because whether a therapy can cross or safely bypass it often determines clinical success, regulatory approval and commercial potential for treatments of brain disorders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEWTON, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that the Company will host a virtual Investor Day on Wednesday, September 16, 2026 at 10:00 a.m. ET.

To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.  

The webcast will be available via this link.  

An archived version of the webcast will be available for at least one year in the Investors section of the Company's website at www.acumenpharm.com.

About Acumen Pharmaceuticals, Inc. 

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its lead investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme’s proprietary ENHANZE^® drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery™ (EBD^®) therapy for Alzheimer’s disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.

Investors:
Alex Braun
abraun@acumenpharm.com

Media: 
ICR Healthcare
AcumenPR@icrhealthcare.com 

FAQ

How can investors participate in Acumen’s virtual Investor Day?

To join the live conference call, investors must register using the provided link. After registration, they will receive the dial-in numbers and a PIN. The company requests that participants complete registration at least one day in advance.

Will a replay of the Investor Day be available?

An archived version of the webcast will be available for at least one year in the Investors section of Acumen’s website at www.acumenpharm.com.